Lv3
300 积分 2024-11-25 加入
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
6个月前
已完结
Ocular Toxicity of Targeted Anticancer Agents
6个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
7个月前
已完结
Gefitinib therapy for non-small cell lung cancer
7个月前
已完结
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
7个月前
已完结
Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma
7个月前
已完结
DsbA-L: A Promising Therapeutic Target for Metabolic Diseases
9个月前
已完结
Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo
9个月前
已完结
A Practical Guide to The Cancer Genome Atlas (TCGA)
10个月前
已完结
皖公网安备34019202002308
